A rational design approach for developing immunomodulators based on CD4 and CD8.
Tretiakova
Anna P
AP
Department of Biochemistry, School of Medicine, MCP Hahnemann University, 245 North 15th Street, Philadelphia, PA 19102, USA.
Albert
Ross H
RH
Jameson
Bradford A
BA
D000276:Adjuvants, Immunologic / Q000138:chemical synthesis* / Q000627:therapeutic use; D000818:Animals; D015703:Antigens, CD / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology*; D016827:CD8 Antigens / Q000276:immunology*; D015195:Drug Design; D006801:Humans; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D015704:CD4 Antigens; D016827:CD8 Antigens